Deferoxamine
Deferoxamine, Desferal (deferoxamine) is a small molecule pharmaceutical. Deferoxamine was first approved as Desferal on 1982-01-01. It is used to treat bone diseases, corneal diseases, and hemochromatosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Deferoxamine, Desferal (discontinued: Deferoxamine, Desferal)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| deferoxamine | ANDA | 2024-04-03 |
| deferoxamine mesylate | ANDA | 2024-11-19 |
| desferal | New Drug Application | 2024-07-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bone diseases | — | D001847 | M89.9 |
| corneal diseases | — | D003316 | H18.9 |
| hemochromatosis | EFO_1000642 | D006432 | E83.11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0895 | Injection, deferoxamine mesylate, 500 mg |
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thalassemia | D013789 | EFO_1001996 | D56 | — | 4 | 2 | 1 | — | 7 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 3 | 2 | 1 | — | 6 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 3 | — | 1 | — | 4 |
| Hemochromatosis | D006432 | EFO_1000642 | E83.11 | — | 1 | 1 | 1 | — | 3 |
| Hemosiderosis | D006486 | — | — | — | 1 | 1 | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iron overload | D019190 | — | — | — | 9 | 2 | — | — | 10 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | — | 2 | — | — | — | 2 |
| Hemolytic anemia | D000743 | — | D55-D59 | — | 1 | — | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 1 | — | — | — | 1 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | — | 1 | — | — | — | 1 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Diamond-blackfan anemia | D029503 | EFO_0004130 | D61.01 | — | 1 | — | — | — | 1 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | — | 1 | — | — | — | 1 |
| Fanconi syndrome | D005198 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deferoxamine |
| INN | deferoxamine |
| Description | Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN |
Identifiers
| PDB | — |
| CAS-ID | 70-51-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL556 |
| ChEBI ID | 4356 |
| PubChem CID | 2973 |
| DrugBank | DB00746 |
| UNII ID | J06Y7MXW4D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Deferoxamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,406 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,652 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use